@phdthesis{Eichler2005,
  author    = {Eichler, Lars},
  title     = {Effects of desialyation on TCR-cross-linking and antigen sensitivity of CD8 positive T lymphocytes},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-19391},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2005},
  abstract  = {The featured experiments focus on changes in T cell membrane glycosylation as a possible means of controlling TCR cross-linking. Taking the long known fact that activated T cells show decreased levels of surface sialic acid as a starting point, differences in ligand binding and cellular reaction upon in vitro stimulation were investigated in na{\"i}ve, activated and enzymatically desialyated CD8+, 2C TCR transgenic mouse lymphocytes. To detect differences in ligand binding lymphocytes were incubated with various concentrations of fluorescently labeled, soluble MHC/Ig fusion proteins until equilibrium was reached. Without previous washing, cells were analyzed by flow cytometry, determined MCF values were normalized to the plateau and fit to a mathematical model of equilibrium binding of divalent ligands to monomorphic receptors (Perelson 1984). Parameters derived from the model fit of binding data show, that neuraminidase treatment of T cells was sufficient to mimic a partially activated phenotype, showing enhanced TCR cross-linking. Enhanced TCR cross-linking was found to be dependent on the presence of CD8, as neuraminidase treatment of DN cells lead to decreased cross-linking. To elucidate the physiological relevance of desialyation induced increases in TCR cross-linking early tyrosine phosphorylation events and proliferative response upon in vitro stimulation of T cells were investigated. Both were found enhanced in neuraminidase treated cells, as compared to native cells. In conclusion the featured experiments suggest a role of surface sialic acid in controlling TCR cross-linking on na{\"i}ve and activated T cells.},
  language  = {en}
}
@article{VogelsangEichlerHuntemannetal.2021,
  author    = {Vogelsang, Anna and Eichler, Susann and Huntemann, Niklas and Masanneck, Lars and B{\"o}hnlein, Hannes and Sch{\"u}ngel, Lisa and Willison, Alice and Loser, Karin and Nieswandt, Bernhard and Kehrel, Beate E. and Zarbock, Alexander and G{\"o}bel, Kerstin and Meuth, Sven G.},
  title     = {Platelet inhibition by low-dose acetylsalicylic acid reduces neuroinflammation in an animal model of multiple sclerosis},
  series = {International Journal of Molecular Sciences},
  volume    = {22},
  journal   = {International Journal of Molecular Sciences},
  number    = {18},
  issn      = {1422-0067},
  doi       = {10.3390/ijms22189915},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-284535},
  year      = {2021},
  abstract  = {Aside from the established immune-mediated etiology of multiple sclerosis (MS), compelling evidence implicates platelets as important players in disease pathogenesis. Specifically, numerous studies have highlighted that activated platelets promote the central nervous system (CNS)-directed adaptive immune response early in the disease course. Platelets, therefore, present a novel opportunity for modulating the neuroinflammatory process that characterizes MS. We hypothesized that the well-known antiplatelet agent acetylsalicylic acid (ASA) could inhibit neuroinflammation by affecting platelets if applied at low-dose and investigated its effect during experimental autoimmune encephalomyelitis (EAE) as a model to study MS. We found that oral administration of low-dose ASA alleviates symptoms of EAE accompanied by reduced inflammatory infiltrates and less extensive demyelination. Remarkably, the percentage of CNS-infiltrated CD4\(^+\) T cells, the major drivers of neuroinflammation, was decreased to 40.98 ± 3.28\% in ASA-treated mice compared to 56.11 ± 1.46\% in control animals at the disease maximum as revealed by flow cytometry. More interestingly, plasma levels of thromboxane A\(_2\) were decreased, while concentrations of platelet factor 4 and glycoprotein VI were not affected by low-dose ASA treatment. Overall, we demonstrate that low-dose ASA could ameliorate the platelet-dependent neuroinflammatory response in vivo, thus indicating a potential treatment approach for MS.},
  language  = {en}
}